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Patients with neuromuscular
diseases ask relatively simple
questions. They want a timely
diagnosis, and information about
prognosis and effects of disease on
their personal functional status.
With respect to treatment, patients
long for a cure but most under-
stand that they will have to rec-
oncile to rehabilitation or even
palliative treatment.
With respect to diagnosis,
neurologists are trained to detect
impairments, neurological signs
and symptoms such as motor
weakness using the MRC scale, or
a Babinski sign. Also, though
usually not in a structured way
neurologists try to evaluate
disability, such as not being able
to go up the stairs or cycling.
Functional status may be mea-
sured with the sickness impact
proﬁle (SIP) or the modiﬁed
Rankin scale. Finally effects of
disease on participation, for
example not being able to work or
taking part in sports, and on per-
ceived health will be estimated.
Measures of disability, participa-
tion and perceived health are
increasingly being used as out-
come measures in clinical trials
[1].
Fatigue may be another under-
estimated symptom of neuromus-
cular disease [2]. That can be
explained by ignorance as most
patients with the exception of
patients with myasthenia gravis or
myotonic dystrophy do not spon-
taneously complain of fatigue.
Many severely handicapped neu-
romuscular patients keep trying to
participate in social life and work.
In contrast, patients with the
chronic fatigue syndrome have no
or little objective signs and maxi-
mal decrease of participation and
perceived health [2]. Yet, if fatigue
would be a common additional
feature of neuromuscular diseases,
neurologists must be aware in or-
der to better comprehend their
patients and to develop new
treatment strategies.
This issue of the Journal of
Neurology contains two papers on
fatigue in hereditary neuromuscu-
lar diseases. Dr. Hagemans did a
cross-sectional study using a
questionnaire with the Fatigue
Severity Scale in 225 patients with
late-onset Pompe disease [3].
About 67% had severe fatigue.
Possible confounding factors were
wheelchair dependency and respi-
ratory support in about half of the
patients, but 59% of patients with-
out these aids also had severe fati-
gue. Previously this group
investigated quality of life in late-
onset Pompe patients using the SF-
36 [4]. Interestingly, they found
that these patients score only
slightly lower than the general
population on the mental health
domains, making depression or
decreased vitality as explanations
for fatigue unlikely [3, 4]. The sec-
ond paper shows that fatigue and
pain can be relevant symptoms in
facioscapulohumeral muscular
dystrophy(FSHD)[5].Bothgroups
suggest that fatigue is probably
underreported in these slowly
progressive neuromuscular dis-
eases.
Some caution with the role of
confounding factors seems justi-
ﬁed. The question whether
patients with late onset Pompe
disease and no respiratory aid
have respiratory insufﬁciency that
explains fatigue, can only be an-
swered by actually measuring
pulmonary function. In FSHD
impaired shoulder function that is
difﬁcult to quantify, will affect
quality of life and could explain
fatigue.
Nevertheless, the notion that
fatigue may be part of the phe-
notype of neuromuscular disease
is important. To my opinion, the
wear and tear from having to live
a life long with the consequences
of a neuromuscular disease may
be one explanation for fatigue.
Severe fatigue will affect partici-
pation and perceived health.
Neurologists must learn to mea-
sure fatigue during history taking.
Neurologists can also develop
interventions. For instance, it has
recently been demonstrated that
simple bicycle exercise training
may help to decrease fatigue in
patients following Guillain–Barre ´
syndrome [6].
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